Norgine presenta los datos para Plenvu® y Xifaxan® durante la United European Gastroenterology Week

  • Siete posters relacionados con PLENVU®  un poster demuestra la eficacia superior de PLENVU® en comparación con el estándar de tratamiento
  • Tres posters relacionados con XIFAXAN®  dos posters mostrados como posters de excelencia y en sesiones de posters ganadoras  

Norgine B.V., destacada compañía farmacéutica europea especializada, presentará datos durante la celebración de la UEG Week Vienna, del 20 al 24 de octubre de 2018:

  • Siete posters relacionados con PLENVU® (polietilenglicol 3350, ascorbato de socio, sulfato de sodio, ácido ascórbico, cloruro de sodio y cloruro de potasio para solución oral) – incluyendo un poster para demostrar la eficacia de limpieza superior de PLENVU® en comparación con MOVIPREP®, SUPREP® y CitraFleet[®]
  • Dos posters de excelencia relacionados con XIFAXAN® (rifaximin) 550mg.

     (Logo: http://mma.prnewswire.com/media/597589/Norgine_Logo.jpg )

Posters relacionados con PLENVU® 

  • Repici A et al. Superior high-quality colon cleansing with 1L NER1006 versus sodium picosulfate + magnesium citrate, 2l polyethylene glycol + ascorbate, or oral sulfate solution: post hoc pooled analysis of three randomised phase 3 clinical trials. #P0159. Lunes 22 de octubre. 12:30 – 13:30 CET
  • Clayton L et al. 1L NER1006 achieves high-quality bowel cleansing with lower total fluid volume intake than standard 2L polyethylene glycol + ascorbate: a post-hoc analysis (OPT). #P0167. Lunes 22 de octubre. 12:30 – 13:30 CET
  • Clayton L et al. 1L NER1006 evening/morning dosing sustains successful colon cleansing in 7 out of 8 patients even 7+ hours after the second dose: post hoc analysis of overnight split-dosing regimens of 1L NER1006 versus 2L polyethylene glycol + ascorbate or oral sulfate solution. #0172. Lunes 22 de octubre. 12:30 – 13:30 CET
  • Hassan C et al. High-quality cleansing improves lesion detection during colonoscopy compared to adequate cleansing: post hoc analysis of 1170 central-reader assessed patients in three randomised phase 3 trials. #P0416. Lunes 22 de octubre. 12:30 – 13:30 CET
  • Manning J et al. Higher Harefield cleansing scale scores are associated with improved lesion detection: post hoc analysis of three randomised and central reader-assessed phase 3 clinical trials. #P0417. Lunes 22 de octubre. 12:30 – 13:30 CET
  • Amlani B et al. Public attitudes to colonoscopy: how much bowel preparation liquid must be drunk before a colonoscopy? #P0460. Lunes 22 de octubre. 12:30 – 13:30 CET
  • Halonen J et al. Overnight or morning only split dosing with 1 L polyethylene glycol NER1006 can deliver 92% or higher rates of successful overall colon cleansing in normal weight and obese patients. #P0607. Lunes 22 de octubre. 12:30 – 13:30 CET.

Posters relacionados con XIFAXAN® 550mg (rifaximin) 

  • Schuchmann M et al. Long term prevention of overt hepatic encephalopathy is possible with lactulose alone but more effective if combined with rifaximin: A systematic review with number needed to treat analyses of randomised controlled trials. #P0032. Poster of Excellence and Poster Champion Session. Lunes 22 de octubre de 12:30 – 13:30 CET, Terminal 4: 14:00 – 15:30 CET, premios: 15.30 CET
  • Currie C et al. Derivation and validation of a statistical model to forecast three-month, all cause mortality in subjects admitted with incident diagnosis of cirrhosis. #P0033. Poster of Excellence and Poster Champion Session. Lunes 22 de octubre, Terminal 2: 12:30 – 13:30 CET, premios: 13.45 CET
  • Currie C et al. Derivation and validation of a statistical model to forecast long term all-cause mortality in people with cirrhosis. #P0034. Lunes 22 de octubre, 12:30 – 13:30 CET.

Síganos en @norgine  

Contacto para medios:  
Isabelle Jouin, Teléfono: +44-(0)-1895-826-237

ÁMSTERDAM, October 19, 2018 /PRNewswire/ —

Share this post:

Contenuto non disponibile
Consenti i cookie cliccando su "Accetta" nel banner"

Recent Posts

Comments are closed.

Utilizzando il sito, accetti l'utilizzo dei cookie da parte nostra. maggiori informazioni

Questo sito utilizza i cookie per fornire la migliore esperienza di navigazione possibile. Continuando a utilizzare questo sito senza modificare le impostazioni dei cookie o cliccando su "Accetta" permetti il loro utilizzo.

Chiudi